Reuters logo
Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln
2017年9月5日 / 晚上8点44分 / 17 天前

Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln

Sept 5 (Reuters) - Novo Nordisk will pay $58.7 million to resolve claims that the drugmaker’s sales staff downplayed the importance of a warning about cancer risks on its diabetes medication Victoza’s label, the U.S. Justice Department said on Tuesday. (Reporting by Nate Raymond in Boston; Editing by Phil Berlowitz)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below